China’s NMPA Approves XTANDI® (enzalutamide) in Metastatic HSPC
Ahsan Arozullah, MD, MPH, Senior Vice President and Head of Oncology Development, Astellas: “We now have compelling, consistent efficacy data for XTANDI in mHSPC across three large Phase 3 trials – ENZAMET, global ARCHES and China ARCHES which have supported approvals around the world. Astellas is deeply committed to bringing XTANDI to those who need it. This approval by the NMPA expands access to a much-needed treatment option for those facing advanced prostate cancer in China.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo